Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.43 +0.46 (+1.72%)

Streaming Delayed Price Updated: 12:39 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Where Will Eli Lilly Stock Be in 10 Years? ↗

March 07, 2026

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗

March 07, 2026

Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now ↗

March 06, 2026

Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.

Via The Motley Fool

Argus Turns Bullish On Pfizer, Highlights GLP-1 And Oncology Pipeline ↗

March 05, 2026

Via Talk Markets

Tariffs News & Market Chaos ↗

March 06, 2026

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

Via The Motley Fool

Topics Economy Government World Trade

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

China Clears Weight-Loss Shot As Pfizer Enters Crowded Market ↗

March 06, 2026

China approves ecnoglutide weight-loss injection linked to Pfizer after trial shows up to 15.4% average weight reduction in adults.

Via Benzinga

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗

March 04, 2026

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.

Via The Motley Fool

Topics Intellectual Property

TechMediaBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Appoints Bat-Sheva Noy as Vice President of Global Sales

March 04, 2026

Via Investor Brand Network

The Dividend Safe Harbor: 2 Stocks to Watch ↗

March 03, 2026

Rising geopolitical tensions, surging oil prices, and increasing volatility are pressuring U.S. equities and driving a shift toward defensive positioning.

Via MarketBeat

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Via The Motley Fool

Topics Intellectual Property

Higher Income or Ironclad Safety? VCIT vs. IEI ↗

March 03, 2026

Explore how portfolio risk, bond type, and diversification set these two fixed income ETFs apart for different investor priorities.

Via The Motley Fool

Topics Bonds ETFs

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4

March 02, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell ↗

March 02, 2026

The reason is so compelling that I actually did buy the stock -- and I have no plans to sell.

Via The Motley Fool

Topics Intellectual Property

Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need ↗

March 01, 2026

Don't follow general market sentiment when it comes to these two stocks.

Via The Motley Fool

Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead? ↗

March 01, 2026

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Via The Motley Fool

Topics Intellectual Property

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗

February 27, 2026

Sorry, Teva, it's not you ... it's me.

Via The Motley Fool

Topics Intellectual Property

Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety

February 27, 2026

As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

The Implementation Pivot: How Accenture Defied the ‘SaaS-pocalypse’ with a Massive AI Rebound

February 27, 2026

As of February 27, 2026, the global technology sector is grappling with a profound identity crisis often dubbed the "SaaS-pocalypse." While many software-as-a-service providers have seen their...

Via MarketMinute

Topics Artificial Intelligence Economy

Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag

February 27, 2026

The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While...

Via MarketMinute

Topics Artificial Intelligence Economy

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

February 27, 2026

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

February 27, 2026

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of...

Via Finterra

Topics Economy

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

February 27, 2026

From Pfizer Inc.

Via Business Wire

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗

February 27, 2026

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Via Stocktwits

Topics Earnings

2 Reasons to Like ZTS (and 1 Not So Much)

February 26, 2026

Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.